Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:ALK
|
| gptkbp:activities |
inhibitor of ALK and RO S1 tyrosine kinases
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:brand |
gptkb:Xalkori
|
| gptkbp:class |
tyrosine kinase inhibitor
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
severe hepatic impairment
concomitant use of strong CY P3 A4 inducers |
| gptkbp:developed_by |
gptkb:Pfizer
|
| https://www.w3.org/2000/01/rdf-schema#label |
crizotinib
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
RO S1-positive metastatic non-small cell lung cancer |
| gptkbp:ingredients |
C21 H22 Cl2 N4 O2 S
|
| gptkbp:interacts_with |
gptkb:HIV_protease_inhibitors
anticoagulants anticonvulsants CY P3 A4 inducers CY P3 A4 inhibitors ergot derivatives macrolide antibiotics st. John's wort |
| gptkbp:is_atype_of |
L01 X E14
|
| gptkbp:is_monitored_by |
electrolytes
liver function tests complete blood count |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:Japan gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
metabolized by CY P3 A4
bioavailability 43% half Life 42 hours |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea vomiting diarrhea rash liver enzyme elevation thrombocytopenia hyperglycemia visual disturbances neutropenia pneumonitis hypophosphatemia peripheral edema QT prolongation |
| gptkbp:targets |
gptkb:ALK_gene_rearrangements
RO S1 gene rearrangements |
| gptkbp:type_of |
877399-52-5
|